131I-metaiodobenzylguanidine treatment in neuroblastoma: report of two cases.
Poor results with 131I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulative administration of 11.9 and 9.2 GBq) has been characterized by a low isotope concentration in the primary tumor and in the multiple bone metastases and by bone marrow uptake with final severe hematological toxicity. A slight decrease in the primary tumor's volume was observed in one patient at a cumulative dose of 85 Gy; there was no change in the other's at 42 Gy. At an initial, greater isotope concentration delivering 103 Gy, some bone metastases displayed a sharp decrease in uptake that persisted in the successive courses. For both patients a progressive spreading of new tumor localisation in the bones and finally in the soft tissues was observed.
Cottino
F
F
Nuclear Medicine Service, Ospedale Mauriziano, Torino, Italy.
Mussa
G C
GC
Madon
E
E
Favero
A
A
Silvestro
L
L
Grazia
G
G
D019797:3-Iodobenzylguanidine; D000008:Abdominal Neoplasms / Q000532:radiotherapy*; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D009447:Neuroblastoma / Q000532:radiotherapy*
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine